Novel Antiviral Peptide Discovery Services at Creative Biolabs to Facilitate SARS-CoV-2 Drug Discovery

Novel Antiviral Peptide Discovery Services at Creative Biolabs to Facilitate SARS-CoV-2 Drug Discovery
Supported by accumulated experience on MERS and SARS-CoV, Creative Biolabs now integrates customized antiviral peptide discovery services into the comprehensive portfolio of SARS-CoV-2 drug discovery services.

Antiviral peptides (AVPs), primary metabolites encoded by ribosomes during the growth of animals, plants, and microorganisms, have inhibitory or killing effects on bacteria, viruses, fungi, parasites and tumor cells. Some AVPs have been shown to have preventive and therapeutic effects against coronavirus (CoV). And recently, studies have also proved that AVPs have versatility in structure and function due to their simple primary structure, and can be used as molecular templates to generate rapid therapeutic drug candidates in the face of COVID-19 or future epidemics.

Creative Biolabs believes that given its unique and promising antiviral activity, the potential use of AVP in the clinical treatment and prevention of COVID-19 will be further explored, thus introducing antiviral peptide discovery services to help accelerate global SARS-CoV-2 drug discovery.

· Peptide Microarray Analysis

The experienced scientist team at Creative Biolabs provides peptide microarray analysis to facilitate research of epitope-mapping, substrate profiling, probing peptide-ligand interactions, protein interaction domains, which are highly useful for drug discovery and development of SARS-CoV-2.

“We promise more stable analysis and higher batch-to-batch reproducibility with low cost, and our peptide sequence design is quite flexible to meet every unique requirement of our clients,” as introduced by a senior scientist at Creative Biolabs.

· ACE2-based Peptide Services 

ACE2 is an important drug target for the researches and treatment of hypertension, heart, kidney, and lung disease. Studies have indicated that ACE2 has been identified to be a functional receptor of the SARS coronavirus. 

Creative Biolabs brings comprehensive services on ACE2-based peptide for SARS-CoV-2 researches. With the help of sophisticated technologies, scientists and technicians, the attrition rate of peptide candidates in the peptide drug discovery projects will be cut down.

· EK1 Fusion Peptide Development Services

EK1 is a pan-CoV fusion inhibitor (peptide), which can inhibit infection of human coronaviruses via inhibiting viral fusion. Creative Biolabs offers EK1 fusion peptide development services to accelerate researches on SARS-CoV-2 and other CoV diseases, including Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS).

In addition to the aforementioned antiviral peptide discovery services, other potential research directions are also covered by standard or custom services, such as SARS-CoV-2 NAb (neutralizing antibody) development service, high-throughput screening (HTS), broad-spectrum SARS-CoV-2 antiviral drug discovery services, etc. More information can be found on

About Creative Biolabs

Empowered by leading technology and years of experience in biomedical science, Creative Biolabs has successfully accomplished numerous challenging projects for customers in requirements with accumulated experience in drug discovery and vaccine development. Especially in the field of antiviral drugs and vaccines, Creative Biolabs provides drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic services at the world-leading level.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 16318306441
State: NY
Country: United States